Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -74.44% | -55.40% | 95.76% | 655.56% | 36.77% |
| Total Depreciation and Amortization | -9.62% | -11.36% | -17.54% | -8.96% | -12.16% |
| Total Amortization of Deferred Charges | 18.18% | 137.31% | -52.00% | -66.67% | -61.40% |
| Total Other Non-Cash Items | 184.71% | 104.31% | -103.51% | 232.58% | 142.86% |
| Change in Net Operating Assets | 196.13% | -224.09% | -53.52% | -21.74% | -299.30% |
| Cash from Operations | 197.25% | -101.50% | 124.00% | 82.11% | -348.91% |
| Capital Expenditure | -129.41% | 41.38% | 36.96% | 66.67% | 85.09% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Investing | -113.64% | -103.04% | 473.91% | 650.93% | 350.88% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | 98.33% | -- | -- | 100.00% |
| Issuance of Common Stock | 50.00% | -97.85% | 0.00% | -- | 14.29% |
| Repurchase of Common Stock | -3,066.67% | -2,966.67% | -3,450.00% | -25.00% | -200.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -22,880.00% | 91.18% | 87.43% | -100.98% | -89.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.06% | -125.53% | 1,577.50% | 244.34% | -312.55% |